The paradoxical role of IL-10 in immunity and cancer.

@article{Mannino2015ThePR,
  title={The paradoxical role of IL-10 in immunity and cancer.},
  author={Mark H Mannino and Ziwen Zhu and Huaping Xiao and Qian Bai and Mark R. Wakefield and Yujiang Fang},
  journal={Cancer letters},
  year={2015},
  volume={367 2},
  pages={
          103-7
        }
}
Interleukin-10 (IL-10) produced by a wide-variety of cells is a highly pleiotropic cytokine. It has been implicated in the pathogenesis and/or development of autoimmune diseases and cancer, although it displays differential effects that seem to be contradictory sometimes. The ultimate role of this cytokine in disease, however, cannot be fully determined until the immunological contexts that regulate its function are further elucidated. In this review, we will discuss a wide variety of evidence… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 61 CITATIONS, ESTIMATED 60% COVERAGE

Diabetes-associated dysregulated cytokines and cancer.

  • Integrative cancer science and therapeutics
  • 2016
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Cytokines and Maternal Omega-3 LCPUFAs Supplementation

Yessica Rodriguez-Santana, Luis Peña-Quintana
  • 2019

FILTER CITATIONS BY YEAR

2015
2019

CITATION STATISTICS

  • 5 Highly Influenced Citations

  • Averaged 16 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 134 REFERENCES

S

E. Zigmond, B. Bernshtein, G. Friedlander, C. R. Walker
  • Yona, K.-W. Kim, et al., Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis, Immunity 40
  • 2014
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

R

K. W. Moore
  • de Waal Malefyt, R.L. Coffman, A. O’Garra, Interleukin-10 and the interleukin-10 receptor, Annu. Rev. Immunol. 19
  • 2001
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

S

F. Y. Yue, R. Dummer, R. Geertsen, G. Hofbauer, E. Laine
  • Manolio, et al., Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules, Int. J. Cancer 71
  • 1997
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

P

M. Matsuda, F. Salazar, M. Petersson, G. Masucci, J. Hansson
  • Pisa, et al., Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression, J. Exp. Med. 180
  • 1994
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

T

M. J. McGeachy, K. S. Bak-Jensen, Y. Chen, C. M. Tato, W. Blumenschein
  • McClanahan, et al., TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell–mediated pathology, Nat. Immunol. 8
  • 2007
VIEW 15 EXCERPTS
HIGHLY INFLUENTIAL

M

F. Rousset, S. Peyrol, E. Garcia, N. Vezzio
  • Andujar, J.-A. Grimaud, et al., Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4, Int. Immunol. 7
  • 1995
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Exploiting natural killer cells for therapy of melanoma.

  • Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • 2015
VIEW 2 EXCERPTS